Yaotan Pharmaceutical

About Yaotan Pharmaceutical

Shanghai Neutan Pharmaceutical Co., Ltd., operating as Yaotan Pharmaceutical, was established in October 2019 and has been recognized as a national high-tech enterprise in China. The company is positioned as a Contract Development and Manufacturing Organization (CDMO), offering a comprehensive suite of one-stop services for both biotechnology firms and traditional pharmaceutical companies. The founding team is composed of seasoned professionals from well-known pharmaceutical enterprises, with an average of over two decades of experience in drug research, development, and industrial operations. This core leadership includes industry experts such as Dr. Liu Xuejun, Dr. David Chen, and Dr. Chen Xiaodong.

Neutan's business model is centered on providing integrated services that span the entire drug development lifecycle. This includes Chemistry, Manufacturing, and Controls (CMC) research services for registered starting materials, Active Pharmaceutical Ingredients (APIs), and formulations. The company also functions as a Contract Manufacturing Organization (CMO), producing cGMP-compliant new drug APIs, as well as clinical samples and commercial products for the global market. Its service portfolio covers chemical synthesis and Contract Research Organization (CRO) services, API process development, analytical method development, quality control, and formulation development and manufacturing. The company has experience with a range of compounds, including those for anti-cancer, anti-viral, and muscle relaxant applications, as well as contrast agents and deuterated reagents. Beyond pharmaceuticals, Neutan also develops health products like multivitamins, and various skincare lines including essences, creams, and freeze-dried products.

Operationally, Neutan has established a significant footprint with research and development centers in Shanghai and Nanjing. Its manufacturing capabilities are distributed across several production bases in provinces such as Hebei, Shandong, Anhui, and Zhejiang. This infrastructure supports the development and production of compounds from milligram to kilogram scales. Key milestones for the company include its establishment in October 2019, receiving Angel Investment in December 2019, and the official opening of its Shanghai R&D center in May 2020. The company continues to expand its manufacturing presence with several facilities, such as those in Shandong, expected to commence production.